{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:46:28Z","timestamp":1792392388095,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,10]],"date-time":"2027-10-10T00:00:00Z","timestamp":1823126400000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["W81XWH-21-1-0590"],"award-info":[{"award-number":["W81XWH-21-1-0590"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["HT9425-23-1-0981"],"award-info":[{"award-number":["HT9425-23-1-0981"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["HT9425-25-1-0239"],"award-info":[{"award-number":["HT9425-25-1-0239"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS123340"],"award-info":[{"award-number":["K23NS123340"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126209","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:04:43Z","timestamp":1791558283000},"page":"126209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Re-treatment of Guillain-Barr\u00e9 syndrome (GBS) in the post-SID-GBS trial era"],"prefix":"10.1016","volume":"491","author":[{"given":"Naomi","family":"Mayman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jns.2026.126209_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16365","article-title":"Guillain-Barr\u00e9 syndrome: a comprehensive review","volume":"31","author":"Bellanti","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"17","key":"10.1016\/j.jns.2026.126209_bb0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jns.2026.126209_bb0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol."},{"issue":"9047","key":"10.1016\/j.jns.2026.126209_bb0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jns.2026.126209_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126209_bb0030","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s13760-024-02518-9","article-title":"Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barr\u00e9 syndrome patients who poorly responded to initial IVIG cycle: a systematic review","volume":"124","author":"Prado","year":"2024","journal-title":"Acta Neurol. Belg."},{"issue":"4","key":"10.1016\/j.jns.2026.126209_bb0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jns.12594","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"28","author":"van Doorn","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"10.1016\/j.jns.2026.126209_bb0040","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0000000000007719","article-title":"Current treatment practice of Guillain-Barr\u00e9 syndrome","volume":"93","author":"Verboon","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126209_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120368","article-title":"Outcomes in Guillain-Barr\u00e9 syndrome following a second therapeutic cycle - a single-Centre retrospective observational study","volume":"441","author":"Faustino","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2026.126209_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70064","article-title":"Guillain-Barr\u00e9 syndrome disability scale","volume":"30","author":"Hughes","year":"2025","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"9","key":"10.1016\/j.jns.2026.126209_bb0055","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.jns.2026.126209_bb0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.126209_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency","volume":"12","author":"Oczko-Walker","year":"2010","journal-title":"J. Clin. Neuromuscul. Dis."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:24:49Z","timestamp":1792391089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":13,"alternative-id":["S0022510X26004910"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126209","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-treatment of Guillain-Barr\u00e9 syndrome (GBS) in the post-SID-GBS trial era","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126209"}}